---
schema_version: "secwatch.filing_event.v1"
accession: "0000064803-23-000036"
form_type: "8-K"
ticker: "CVS"
cik: "0000064803"
company_name: "CVS HEALTH Corp"
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:55:23.043211+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# CVS Health reaffirms FY2023 GAAP EPS $6.53-$6.75, Adjusted EPS $8.50-$8.70, CFO $12.5B-$13.5B

## Summary
- Reaffirms FY2023 GAAP diluted EPS range $6.53–$6.75, unchanged from prior guidance.
- Reaffirms FY2023 Adjusted EPS range $8.50–$8.70, unchanged.
- Reaffirms FY2023 cash flow from operations guidance $12.5B–$13.5B.
- Management to present at investor meeting on September 12, 2023; webcast available.

## SEC filing metadata
- accession: 0000064803-23-000036
- form_type: 8-K
- ticker: CVS
- cik: 0000064803
- company_name: CVS HEALTH Corp
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/64803/000006480323000036/0000064803-23-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/64803/000006480323000036/cvs-20230911.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000064803-23-000036
- JSON: https://secwatch.observer/filing/0000064803-23-000036.json
- Plain text: https://secwatch.observer/filing/0000064803-23-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.